Population
Cancer cells and noncancerous tissues (focus on doxorubicin therapy)
Design
Review
Authors
Loading...
Should not yet change doxorubicin practice; leaves open optimal strategies to enhance tumor selectivity while curbing cardiotoxicity.
This review outlines strategies to enhance the anti-cancer efficacy of doxorubicin while mitigating its dose-limiting cardiotoxicity.
Hanušová et al. (2011) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: